Novel phosphoinositide 3-kinase d,g inhibitor: Potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 2, 2014, Pages 271-280

  Boyle, David L ^a   Kim, Hae Rim ^a,b   Topolewski, Katharyn ^a   Bartok, Beatrix ^a   Firestein, Gary S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Konkuk University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DUVELISIB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ASSESSMENT; COLLAGEN-INDUCED ARTHRITIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOASSAY; JOINT RADIOGRAPHY; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; WESTERN BLOTTING;

EID: 84893092808     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.205955     Document Type: Article

References (49)

1. Alcázar I, Marqués M, Kumar A, Hirsch E, Wymann M, Carrera AC, and Barber DF (2007) Phosphoinositide 3-kinase gamma participates in T cell receptor-induced T cell activation. J Exp Med 204:2977-2987.
2. Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C, Kuehn N, Gray A, Giddings J, and Peskett E, et al. (2004) Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 431:1007-1011.
3. Barber DF, Bartolomé A, Hernandez C, Flores JM, Redondo C, Fernandez-Arias C, Camps M, Rückle T, Schwarz MK, and Rodríguez S, et al. (2005) PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med 11:933-935.
4. Barberis L, Pasquali C, Bertschy-Meier D, Cuccurullo A, Costa C, Ambrogio C, Vilbois F, Chiarle R, Wymann M, and Altruda F, et al. (2009) Leukocyte transmigration is modulated by chemokine-mediated PI3Kgamma-dependent phosphorylation of vimentin. Eur J Immunol 39:1136-1146.
5. Barbi J, Cummings HE, Lu B, Oghumu S, Rückle T, Rommel C, Lafuse W, Whitacre CC, and Satoskar AR (2008) PI3Kgamma (PI3Kgamma) is essential for efficient induction of CXCR3 on activated T cells. Blood 112:3048-3051.
6. Bartok B, Boyle DL, Liu Y, Ren P, Ball ST, Bugbee WD, Rommel C, and Firestein GS (2012) PI3 kinase d is a key regulator of synoviocyte function in rheumatoid arthritis. Am J Pathol 180:1906-1916.
7. Boyle DL, Kowaluk EA, Jarvis MF, Lee CH, Bhagwat SS, Williams M, and Firestein GS (2001) Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis. J Pharmacol Exp Ther 296:495-500.
8. Boyle DL, Rosengren S, Bugbee W, Kavanaugh A, and Firestein GS (2003) Quantitative biomarker analysis of synovial gene expression by real-time PCR. Arthritis Res Ther 5:R352-R360.
9. Brand DD, Kang AH, and Rosloniec EF (2003) Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol 25:3-18.
10. Camps M, Rückle T, Ji H, Ardissone V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, and Françon B, et al. (2005) Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11:936-943.
11. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, Humphries LA, Rawlings D, Reynolds H, and Vigorito E, et al. (2002) A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 196:753-763.
12. Firestein GS, Paine MM, and Littman BH (1991) Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids. Arthritis Rheum 34:1094-1105.
13. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, and Wallenstein G, et al. (2012) Phase IIb doseranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64:617-629.
14. Fruman DA and Cantley LC (2002) Phosphoinositide 3-kinase in immunological systems. Semin Immunol 14:7-18.
15. Gruen M, Rose C, König C, Gajda M, Wetzker R, and Bräuer R (2010) Loss of phosphoinositide 3-kinase gamma decreases migration and activation of phagocytes but not T cell activation in antigen-induced arthritis. BMC Musculoskelet Disord 11:63.
16. Hammaker D, Topolewski K, Edgar M, Yoshizawa T, Fukushima A, Boyle DL, Burak EC, Sah RL, and Firestein GS (2012) Decreased collagen-induced arthritis severity and adaptive immunity in MKK-6-deficient mice. Arthritis Rheum 64: 678-687.
17. Hammaker DR, Boyle DL, Inoue T, and Firestein GS (2007) Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes. Arthritis Res Ther 9:R57.
18. Han Z, Boyle DL, Manning AM, and Firestein GS (1998) AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28:197-208.
19. Hayer S, Pundt N, Peters MA, Wunrau C, Kuhnel I, Neugebauer K, Strietholt S, Zwerina J, Korb A, and Penninger J, et al. (2009) PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis. FASEB J 23:4288-4298.
20. Henley T, Kovesdi D, and Turner M (2008) B-cell responses to B-cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta. Eur J Immunol 38:3543-3548.
21. Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, Sozzani S, Mantovani A, Altruda F, and Wymann MP (2000) Central role for G proteincoupled phosphoinositide 3-kinase gamma in inflammation. Science 287:1049-1053.
22. Ito S, Kimura K, Haneda M, Ishida Y, Sawada M, and Isobe K (2007) Induction of matrix metalloproteinases (MMP3, MMP12 and MMP13) expression in the microglia by amyloid-beta stimulation via the PI3K/Akt pathway. Exp Gerontol 42: 532-537.
23. Joe B, Griffiths MM, Remmers EF, and Wilder RL (1999) Animal models of rheumatoid arthritis and related inflammation. Curr Rheumatol Rep 1:139-148.
24. Jou ST, Carpino N, Takahashi Y, Piekorz R, Chao JR, Carpino N, Wang D, and Ihle JN (2002) Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 22:8580-8591.
25. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, and Pascual-Ramos V, et al. (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64:970-981.
26. Kulkarni S, Sitaru C, Jakus Z, Anderson KE, Damoulakis G, Davidson K, Hirose M, Juss J, Oxley D, and Chessa TA, et al. (2011) PI3Kb plays a critical role in neutrophil activation by immune complexes. Sci Signal 4:ra23.
27. Kunz M and Ibrahim SM (2009) Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm 2009: 979258.
28. Kurebayashi Y, Nagai S, Ikejiri A, Ohtani M, Ichiyama K, Baba Y, Yamada T, Egami S, Hoshii T, and Hirao A, et al. (2012) PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORg. Cell Rep 1:360-373.
29. Laffargue M, Calvez R, Finan P, Trifilieff A, Barbier M, Altruda F, Hirsch E, and Wymann MP (2002) Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity 16:441-451.
30. Li Z, Jiang H, Xie W, Zhang Z, Smrcka AV, and Wu D (2000) Roles of PLC-beta2 and-beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 287:1046-1049.
31. Luo Y, Boyle DL, Hammaker D, Edgar M, Franzoso G, and Firestein GS (2011) Suppression of collagen-induced arthritis in growth arrest and DNA damageinducible protein 45b-deficient mice. Arthritis Rheum 63:2949-2955.
32. Manning BD and Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261-1274.
33. Mohammed FF, Smookler DS, and Khokha R (2003) Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis 62 (Suppl 2):ii43-ii47.
34. Oak JS, Deane JA, Kharas MG, Luo J, Lane TE, Cantley LC, and Fruman DA (2006) Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase. Proc Natl Acad Sci USA 103:16882-16887.
35. Okada T, Sakuma L, Fukui Y, Hazeki O, and Ui M (1994) Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. J Biol Chem 269:3563-3567.
36. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, and Waterfield MD, et al. (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297:1031-1034.
37. Pirola L, Zvelebil MJ, Bulgarelli-Leva G, Van Obberghen E, Waterfield MD, and Wymann MP (2001) Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling. J Biol Chem 276:21544-21554.
38. Randis TM, Puri KD, Zhou H, and Diacovo TG (2008) Role of PI3Kdelta and PI3Kgamma in inflammatory arthritis and tissue localization of neutrophils. Eur J Immunol 38:1215-1224.
39. Sadhu C, Masinovsky B, Dick K, Sowell CG, and Staunton DE (2003) Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 170:2647-2654.
40. Sasaki T, Irie-Sasaki J, Jones RG, Oliveira-dos-Santos AJ, Stanford WL, Bolon B, Wakeham A, Itie A, Bouchard D, and Kozieradzki I, et al. (2000) Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287:1040-1046.
41. Schuerwegh AJ, Ioan-Facsinay A, Dorjée AL, Roos J, Bajema IM, van der Voort EI, Huizinga TW, and Toes RE (2010) Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad Sci USA 107:2586-2591.
42. Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, Ager A, Okkenhaug K, Hagenbeek TJ, Spits H, and Cantrell DA (2008) Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 9:513-521.
43. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, and Magilavy DB (2010) An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 363:1303-1312.
44. Winkler DG, Faia KL, DiNitto JP, Ali JA, White KF, Brophy EE, Pink MM, Proctor JL, Lussier J, and Martin CM, et al. (2013) Inhibition of PI3K-d and PI3K-g by IPI-145 abrogates the adaptive and innate immune response and suppresses autoimmune and inflammatory disease models. Chem Biol 20:1364-1374.
45. Wu P and Hu YZ (2010) PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Curr Med Chem 17:4326-4341.
46. Yanaba K, Hamaguchi Y, Venturi GM, Steeber DA, St Clair EW, and Tedder TF (2007) B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol 179:1369-1380.
47. Yu J, Zhang Y, McIlroy J, Rordorf-Nikolic T, Orr GA, and Backer JM (1998) Regulation of the p85/p110 phosphatidylinositol 39-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol 18:1379-1387.
48. Zhang TT, Makondo KJ, and Marshall AJ (2012) p110d phosphoinositide 3-kinase represses IgE switch by potentiating BCL6 expression. J Immunol 188:3700-3708.
49. Zhang TT, Okkenhaug K, Nashed BF, Puri KD, Knight ZA, Shokat KM, Vanhaesebroeck B, and Marshall AJ (2008) Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production. J Allergy Clin Immunol 122: 811.e2-819.e2.